The use of potentially interacting supplement–drug pairs in adults with type 2 diabetes: A large population-based cohort study in the UK Biobank
Authors' conclusion
Real-world data suggests that most adults with T2D who concurrently used supplements and drugs were on potentially interacting supplement-drug combinations, with the potential of causing adverse outcomes such as incident hepatic diseases. Clinicians should communicate with patients and assess the potential risk of supplement-drug interactions in clinical settings.
Study context
- Population
- Adults with T2D in the UK Biobank
- Participants
- 26,394 adults
- Exposure
- Use vs no use of potentially interacting supplement–drug pairs
- Outcome
- Patterns of use of potentially interacting supplement–drug pairs
Methodological detailsUK Biobank, Cox models
- UK Biobank
- Cox models
Main finding
As reported in the abstract
Use of potentially interacting supplement–drug pairs
- Supplement users
- 48.5 %
- Supplement users taking potentially interacting supplement–drug pairs
- 85.0 %
- Potential interactions reducing effects of glucose-lowering drugs
- 50.7 %
- Potential interactions related to hypotension
- 49.8 %
- Potential interactions related to bleeding
- 50.4 %
- Potential interactions related to hepatotoxicity
- 34.8 %
Observational data: associations, not effects.
Further findings
Incident hepatic diseases with use of potentially interacting supplement–drug pairs
- HR (95% CI 1.10-1.44), P < 0.001
- 1.26
- Exploratory analysis
Original publication
The use of potentially interacting supplement–drug pairs in adults with type 2 diabetes: A large population-based cohort study in the UK Biobank. Diabetes Res Clin Pract. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →